GPCRs (G protein-coupled receptors), also known as 7 transmembrane domain receptors, are the largest receptor family in the human genome, with ≈800 members. GPCRs regulate nearly every aspect of human ...
The first comprehensive single-cell atlas of bone-innervating sensory neurons has identified their dual role in reporting and repairing bone damage, providing a potential target for drugs that might ...
When a house catches on fire, we assume that a smoke alarm inside will serve one purpose and one purpose only: warn the occupants of danger. But imagine if the device could transform into something ...
Zidesamtinib targets ROS1-positive NSCLC, showing promise in overcoming resistance mutations and CNS metastases with brain penetrance. The ARROS-1 trial demonstrated significant response rates in TKI ...
Humans have approximately 20,000 human protein-coding genes, and the proteins they express span a concentration range of ~12 logs. Yet only 0.1% of proteins contribute to 99% of the total plasma ...
Plants must defend themselves against relentless insect herbivores. A new study uncovers how tea plants (Camellia sinensis), one of the world's most valuable crops, activate their immune defenses at ...
GRKs (GPCR [G protein–coupled receptor] kinases) are key regulators of GPCR signaling. Because GPCRs are targeted by approximately 40% of clinical drugs, GRKs also represent therapeutic targets for ...
BEIJING--(BUSINESS WIRE)--Beijing Avistone Biotechnology Co., Ltd (also referred to as “Avistone Biotechnology” or “Avistone”), an innovative biotechnology company focused on precision oncology ...
Taletrectinib emerges as a groundbreaking treatment for ROS1-mutant NSCLC, offering hope with its CNS activity and lower neurological side effects. The landscape of treatment for ROS1-mutant non–small ...
Hundreds of leucine-rich repeat receptor kinases (LRR-RKs) have evolved to control diverse processes of growth, development, and immunity in plants; the mechanisms that link LRRRKs to distinct ...
Announcing a new publication for Acta Materia Medica journal. A preclinical study has developed a precision nano-intervention strategy targeting tumor-associated nerves to destroy nerve-fueled tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results